| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ataibeckley Inc. (ATAI) has 13 insiders with recent SEC Form 4 filings, including 3 buys and 7 sells. ATAI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 53.41M | $214.18M | - | |
| Dir | 456.0K | $1.83M | - | |
| Other | 372.7K | $1.49M | -42,579 | |
| Other | 217.8K | $873.3K | - | |
| Dir | 206.0K | $826.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | Craig Kevin James | Chief Medical Officer | Sale+OE | 42,579 | $5.00 | $212,895.00 | -83.5% | - | - | |
| Aug 14, 2025 | Apeiron Investment Group Ltd.48 | 10% Owner | Buy | 8,675,799 | $2.19 | $18,999,999.81 | +20.5% | +8.0% | - | |
| Mar 24, 2025 | Apeiron Investment Group Ltd.48 | 10% Owner | Buy | 1,800,000 | $1.40 | $2,520,000.00 | +4.4% | +28.7% | +115.3% | |
| Mar 21, 2025 | Kirpekar Sahil | Chief Business Officer | Sell | 48,563 | $1.35 | $65,560.05 | -29.6% | +71.0% | +140.7% | |
| Mar 21, 2025 | Craig Kevin James | Chief Medical Officer | Sell | 11,563 | $1.35 | $15,610.05 | -57.8% | +71.0% | +140.7% | |
| Mar 21, 2025 | Rao Srinivas | See Remarks | Sell | 75,418 | $1.35 | $101,814.30 | -26.2% | +71.0% | +140.7% | |
| Mar 21, 2025 | Johnson Anne Nagengast | Chief Financial Officer | Sell | 33,545 | $1.35 | $45,285.75 | -19.3% | +71.0% | +140.7% | |
| Mar 21, 2025 | Short Glenn Frank | Chief Scientific Officer | Sell | 13,161 | $1.35 | $17,767.35 | -23.7% | +71.0% | +140.7% | |
| Feb 14, 2025 | Apeiron Investment Group Ltd.48 | 10% Owner | Buy | 10,835,718 | $2.10 | $22,755,007.80 | +36.5% | -29.1% | +55.2% | |
| Sep 26, 2024 | Atai Life Sciences N.V. | 10% Owner | Sell | 2,660,000 | $6.05 | $16,093,000.00 | -27.8% | +5.0% | +342.9% |